Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
EUR 62.2
(0.97%)
EUR 62.2
(0.97%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 483.34 Million EUR | -2.7% |
| 2022 | 496.74 Million EUR | 36.67% |
| 2021 | 363.45 Million EUR | 63.93% |
| 2020 | 221.71 Million EUR | 12.84% |
| 2019 | 196.49 Million EUR | 112.73% |
| 2018 | 92.36 Million EUR | -6.95% |
| 2017 | 99.26 Million EUR | 21.57% |
| 2016 | 81.65 Million EUR | 5.78% |
| 2015 | 77.19 Million EUR | -45.27% |
| 2014 | 141.05 Million EUR | 7.84% |
| 2013 | 130.79 Million EUR | 5.14% |
| 2012 | 124.4 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 110.31 Million EUR | 28.77% |
| 2024 Q1 | 85.67 Million EUR | -34.88% |
| 2023 Q1 | 120.2 Million EUR | -29.57% |
| 2023 Q2 | 85.39 Million EUR | -28.96% |
| 2023 Q3 | 128.89 Million EUR | 50.94% |
| 2023 Q4 | 131.55 Million EUR | 2.07% |
| 2023 FY | 464.08 Million EUR | -6.57% |
| 2022 Q4 | 170.67 Million EUR | 53.68% |
| 2022 Q3 | 111.06 Million EUR | 15.83% |
| 2022 FY | 496.74 Million EUR | 36.67% |
| 2022 Q2 | 95.88 Million EUR | -19.51% |
| 2022 Q1 | 119.12 Million EUR | 4.55% |
| 2021 Q2 | 78.48 Million EUR | 21.5% |
| 2021 Q4 | 113.93 Million EUR | 7.04% |
| 2021 Q3 | 106.44 Million EUR | 35.63% |
| 2021 Q1 | 64.59 Million EUR | 3.23% |
| 2021 FY | 363.45 Million EUR | 63.93% |
| 2020 Q1 | 54.91 Million EUR | -0.51% |
| 2020 Q4 | 62.57 Million EUR | -0.42% |
| 2020 Q3 | 62.83 Million EUR | 10.61% |
| 2020 FY | 221.71 Million EUR | 12.84% |
| 2020 Q2 | 56.8 Million EUR | 3.45% |
| 2019 FY | 196.49 Million EUR | 112.73% |
| 2019 Q4 | 55.2 Million EUR | 0.82% |
| 2019 Q3 | 54.75 Million EUR | -0.28% |
| 2019 Q2 | 54.9 Million EUR | 17.87% |
| 2019 Q1 | 46.57 Million EUR | 12.32% |
| 2018 Q4 | 41.46 Million EUR | -8.31% |
| 2018 Q3 | 45.22 Million EUR | 10.8% |
| 2018 Q2 | 40.81 Million EUR | -6.28% |
| 2018 Q1 | 43.55 Million EUR | 7.15% |
| 2018 FY | 92.36 Million EUR | -6.95% |
| 2017 Q3 | 37.68 Million EUR | -10.98% |
| 2017 Q1 | 41.19 Million EUR | 7.46% |
| 2017 FY | 99.26 Million EUR | 21.57% |
| 2017 Q4 | 40.64 Million EUR | 7.87% |
| 2017 Q2 | 42.32 Million EUR | 2.76% |
| 2016 Q2 | 39.73 Million EUR | 10.1% |
| 2016 FY | 81.65 Million EUR | 5.78% |
| 2016 Q4 | 38.33 Million EUR | 7.51% |
| 2016 Q3 | 35.65 Million EUR | -10.27% |
| 2016 Q1 | 36.09 Million EUR | -3.91% |
| 2015 FY | 77.19 Million EUR | -45.27% |
| 2015 Q4 | 37.55 Million EUR | 6.28% |
| 2015 Q3 | 35.34 Million EUR | -7.15% |
| 2015 Q2 | 38.06 Million EUR | 7.52% |
| 2015 Q1 | 35.39 Million EUR | -5.76% |
| 2014 Q4 | 37.55 Million EUR | 12.25% |
| 2014 FY | 141.05 Million EUR | 7.84% |
| 2014 Q1 | 34.14 Million EUR | 8.24% |
| 2014 Q2 | 35.88 Million EUR | 5.11% |
| 2014 Q3 | 33.46 Million EUR | -6.76% |
| 2013 Q2 | 36.49 Million EUR | 19.27% |
| 2013 Q4 | 31.54 Million EUR | -1.92% |
| 2013 FY | 130.79 Million EUR | 5.14% |
| 2013 Q3 | 32.16 Million EUR | -11.87% |
| 2013 Q1 | 30.59 Million EUR | 6.84% |
| 2012 Q4 | 28.63 Million EUR | 0.0% |
| 2012 FY | 124.4 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Boiron SA | 358.08 Million EUR | -34.981% |
| Vetoquinol SA | 291.37 Million EUR | -65.881% |
| Valneva SE | 52.83 Million EUR | -814.783% |
| AB Science S.A. | 587 Thousand EUR | -82241.397% |
| Nanobiotix S.A. | 42.35 Million EUR | -1041.093% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -36351.282% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 15716.931% |
| BioSenic S.A. | 543 Thousand EUR | -88913.628% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -12249.106% |
| Formycon AG | 23.3 Million EUR | -1973.993% |